<DOC>
	<DOCNO>NCT00517439</DOCNO>
	<brief_summary>This 7 arm study determine optimal treatment combination , base efficacy safety . Patients chronic hepatitis C ( CHC ) , genotype 1 , randomize one 7 treatment group . Groups 1 , 2 , 4 , 5 6 receive triple combination treatment HCV polymerase inhibitor pro-drug ( dose 500 , 1000 1500mg po bid ) plus PEGASYS ( 90 180 microgram sc weekly ) plus Copegus ( 1000 1200mg po qd ) 24 week , follow 24 week open label Standard Care ( PEGASYS 180 microgram sc weekly plus Copegus 1000/1200mg po qd ) . Group 3 receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 microgram sc weekly plus Copegus 1000/1200mg po qd 24 week ; 24 week , achieve rapid virological response ( RVR ) stop medication , non-RVR patient remain triple combination additional 24 week . Group 7 receive standard care ( SOC ) 48 week . There 24 week period treatment-free follow-up treatment group . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Hepatitis C Virus ( HCV ) Polymerase Inhibitor Pro-Drug Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS Patients With Chronic Hepatitis C Genotype 1 Infection .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1865 year age ; chronic hepatitis C , genotype 1 ; chronic liver disease consistent CHC ; compensate liver disease . infection HCV genotype genotype 1 ; previous treatment CHC ; medical condition associate chronic liver disease CHC ; HIV , hepatitis A , hepatitis B infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>